ToolsPrintable tool
Treatment history
Record treatment dates, exact products and formulations when known, the course used, response, return, unwanted effects, and questions for care without ranking what to try next.
Safety and when to get care
This route is based on the observable trigger and does not identify a diagnosis.
Care tier: Routine care
- Observable trigger
- Vaginal symptoms persist after an over-the-counter yeast treatment, return less than 2 months after treatment, or continue or recur after prescribed treatment.
- What to do
- Arrange a clinician visit for evaluation and testing instead of repeating self-treatment without reassessment.
- Exact population
- adolescents and adults in the United States with vaginal or vulvar symptoms after yeast treatment
- Not covered here
- people with a simultaneous medical emergency or acute mental-health crisis, who need the applicable emergency route
Care tier: Routine care
- Observable trigger
- The person is pregnant, might be pregnant, or becomes pregnant while considering or taking treatment for vaginal yeast symptoms.
- What to do
- Contact the pregnancy-care clinician before self-treating; do not use the exact fluconazole products in DailyMed setid 737e0fac-a2d2-4053-a0d7-edbfb6248f69 unless the clinician directs their use, and report pregnancy during use promptly.
- Exact population
- pregnant or possibly pregnant people in the United States with vaginal yeast symptoms
- people who become pregnant while taking the exact referenced fluconazole tablet or suspension products
- Not covered here
- nonpregnant people not planning pregnancy
- users of other products whose labels were not checked by this record
In this pathway
- Parent problem or section
- Tools
- Current topic
- Treatment historyCurrent
Sources behind these conclusions
Claim: Recording symptom timing and pattern, episode count, menstrual context, relevant exposures, prior test results, treatments used, adherence, adverse effects, and response supports evaluation of recurrent or unresolved vulvovaginal symptoms, but the history cannot establish the cause without appropriate examination and testing.
Supported · Moderate — CDC specifies the history elements relevant to vaginal symptoms while warning that history alone is diagnostically insufficient. ISSVD ties recurrence decisions to episode pattern, testing, species, and treatment response; a 2026 qualitative study describes documentation, test access, and interpretation as parts of the diagnostic pathway but cannot by itself establish outcome benefit from a tool.
Sources for this claim
- Sexually Transmitted Infections Treatment Guidelines, 2021: Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge (Guideline)
- International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis (Guideline)
- It's not just thrush, it's recurrent thrush: a qualitative study of patient and clinician perspectives on diagnosing recurrent vulvovaginal candidiasis (Observational study)
Claim: No improvement, only partial improvement, symptom return after treatment, worsening, or new vulvovaginal symptoms do not confirm residual yeast; they change the situation to unresolved symptoms that require reassessment of the diagnosis and appropriate testing.
Supported · Moderate — CDC requires clinical evaluation and testing for persistent symptoms after over-the-counter treatment or recurrence within two months and follow-up for persistent or recurrent symptoms. ISSVD emphasizes culture and exclusion of other causes in complicated or persistent presentations. The exact urgency attached to worsening or new observable symptoms remains locale-safety owned.
Sources for this claim
- Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis (Guideline)
- Sexually Transmitted Infections Treatment Guidelines, 2021: Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge (Guideline)
- International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis (Guideline)
Worksheet
Date
Leave blank if unknown and note an approximate date below.
Leave blank if the course has not ended or the date is unknown.
Copy the brand or generic name, strength, dosage form, and route from the package or prescription when available; otherwise write “unknown.”
Record how much, how often, for how long, and whether you completed, stopped, changed, or missed part of the course.
Describe no improvement, partial or full improvement, worsening, or new symptoms in your own words, with approximate dates when useful.
If symptoms returned, note when and how they compared with the earlier problem. Leave blank if this did not happen or is unknown.
Record what happened, when it began, and what action you took. This field does not determine whether the product caused it.
List what you want clarified about the diagnosis, result, product, course, unwanted effects, reassessment, or possible next options.
How to use this record
Complete one sheet for each treatment course. Copy exact details when available, mark uncertainty openly, and take the sheet to a clinician or pharmacist. It is a conversation aid, not a treatment decision or proof of a diagnosis.
What the worksheet covers
The fields provide date space and organize the exact product or formulation, course, response, symptom return, unwanted effects, and questions for care. They do not calculate, compare, or interpret entries.
Privacy boundary
Nothing entered is sent or saved. Browser-entered values exist only in the current document and disappear when you navigate away, reload, or close the page.
Method and sources
The prompts reflect the structured treatment-history elements in the cited clinical guidance and evidence about reassessment after persistent or returned symptoms. Exact product details can matter, but this record does not interpret a label or select a treatment. The linked evidence methodology explains how Candipedia selects, checks, and updates sources.
Sources
View all 5 sources
- Sexually Transmitted Infections Treatment Guidelines, 2021: Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge
- Source type
- Guideline
- Published
- 2021-07-23
- Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis
- Source type
- Guideline
- Published
- 2021-07-23
- International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis
- Source type
- Guideline
- Published
- 2023-03-01
- It's not just thrush, it's recurrent thrush: a qualitative study of patient and clinician perspectives on diagnosing recurrent vulvovaginal candidiasis
- Source type
- Observational study
- Published
- 2026-06-01
- FLUCONAZOLE tablet; FLUCONAZOLE powder, for suspension
- Source type
- Official product information
- Published
- 2026-04-02